The complex pathophysiology of acquired aplastic anaemia

Clinical and Experimental Immunology

Volumn 180, Issue 3, 2015, Pages 361-370

  Zeng, Y ^a   Katsanis, E ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Aplastic anemia; Bone marrow mesenchymal stem cell; Hematopoietic stem progenitor cell, immune dysregulation

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CYTOKINE; GAMMA INTERFERON; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 17; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED APLASTIC ANEMIA; APLASTIC ANEMIA; BONE MARROW DEPRESSION; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL KILLING; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HELPER CELL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HLA TYPING; HUMAN; IMMUNE RESPONSE; IMMUNOGENETICS; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MOLECULAR BIOLOGY; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TELOMERE; TH17 CELL; ANEMIA, APLASTIC; ANIMAL; DISEASE PREDISPOSITION; GENETIC PREDISPOSITION; IMMUNOLOGY; IMMUNOMODULATION; MESENCHYMAL STROMA CELL; METABOLISM; T LYMPHOCYTE SUBPOPULATION;

ANEMIA, APLASTIC; ANIMALS; CYTOKINES; DISEASE SUSCEPTIBILITY; GENETIC PREDISPOSITION TO DISEASE; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNITY, INNATE; IMMUNOMODULATION; MESENCHYMAL STROMAL CELLS; T-LYMPHOCYTE SUBSETS;

EID: 84929516381     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12605     Document Type: Review

References (90)

1. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood 2012; 120:1185-96.
2. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108:2509-19.
3. Passweg JR, Tichelli A. Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling? Haematologica 2009; 94: 310-2.
4. Nakao S, Takamatsu H, Chuhjo T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood 1994; 84: 4257-61.
5. Dhaliwal JS, Wong L, Kamaluddin MA, et al. Susceptibility to aplastic anemia is associated with HLA-DRB1*1501 in an aboriginal population in Sabah, Malaysia. Hum Immunol 2011; 72: 889-92.
6. Nakao S, Takami A, Takamatsu H, et al. Isolation of a T-cell clone showing HLA-DRB1*0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood 1997; 89:3691-9.
7. Chen CLu S, Luo M, et al. Correlations between HLA-A, HLAB and HLA-DRB1 allele polymorphisms and childhood susceptibility to acquired aplastic anemia. Acta Haematol 2012; 128: 23-7.
8. Fuhrer M, Durner J, Brunnler G, et al. HLA association is different in children and adults with severe acquired aplastic anemia. Pediatr Blood Cancer 2007; 48:186-91. [CrossRef]
9. Yari F, Sobhani M, Vaziri MZ, et al. Association of aplastic anaemia and Fanconi's disease with HLA-DRB1 alleles. Int J Immunogenet 2008; 35:453-6.
10. Rehman S, Saba N, Khalilullah, et al. The frequency of HLA class I and II alleles in Pakistani patients with aplastic anemia. Immunol Invest 2009; 38:812-19.
11. Song EY, Kang HJ, Shin HY, et al. Association of human leukocyte antigen class II alleles with response to immunosuppressive therapy in Korean aplastic anemia patients. Hum Immunol 2010;71:88-92.
12. Sugimori C, Yamazaki H, Feng X, et al. Roles of DRB1*1501 and DRB1*1502 in the pathogenesis of aplastic anemia. Exp Hematol 2007; 35:13-20.
13. Nakao S, Takami A, Sugimori N, et al. Response to immunosuppressive therapy and an HLA-DRB1 allele in patients with aplastic anaemia: HLA-DRB1*1501 does not predict response to antithymocyte globulin. Br J Haematol 1996; 92:155-8.
14. Zanelli E, Breedveld FC, de Vries RR. HLA association with autoimmune disease: a failure to protect? Rheumatology (Oxf) 2000; 39:1060-6.
15. Sutton KS, Shereck EB, Nemecek ER, et al. Immune markers of disease severity and treatment response in pediatric acquired aplastic anemia. Pediatr Blood Cancer 2013; 60:455-60.
16. Zeng W, Kajigaya S, Chen G, et al. Transcript profile of CD41 and CD81 T cells from the bone marrow of acquired aplastic anemia patients. Exp Hematol 2004; 32:806-14.
17. Kordasti S, Marsh J, Al-Khan S, et al. Functional characterization of CD41 T cells in aplastic anemia. Blood 2012; 119:2033-43.
18. Ren J, Hou XY, Ma SH, et al. Elevated expression of CX3C chemokine receptor 1 mediates recruitment of T cells into bone marrow of patients with acquired aplastic anaemia. J Intern Med 2014; 276:512-24.
19. Xing L, Liu C, Fu R, et al. CD81HLA-DR1 T cells are increased in patients with severe aplastic anemia. Mol Med Rep 2014; 10:1252-8.
20. Piao W, Grosse J, Czwalinna A, et al. Antigen-recognition sites of micromanipulated T cells in patients with acquired aplastic anemia. Exp Hematol 2005; 33:804-10.
21. Risitano AM, Maciejewski JP, Green S, et al. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet 2004; 364:355-64.
22. Kochenderfer JN, Kobayashi S, Wieder ED, et al. Loss of Tlymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002; 100: 3639-45.
23. Wlodarski MW, Gondek LP, Nearman ZP, et al. Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood 2006; 108:2632-41.
24. Schuster FR, Hubner B, Fuhrer M, et al. Highly skewed T-cell receptor V-beta chain repertoire in the bone marrow is associated with response to immunosuppressive drug therapy in children with very severe aplastic anemia. Blood Cancer J 2011; 1: e8.
25. Li B, Liu S, Niu Y, et al. Altered expression of the TCR signaling related genes CD3 and FcepsilonRIgamma in patients with aplastic anemia. J Hematol Oncol 2012; 5:6.
26. Solomou EE, Wong S, Visconte V, et al. Decreased TCR zetachain expression in T cells from patients with acquired aplastic anaemia. Br J Haematol 2007; 138:72-6.
27. Giannakoulas NC, Karakantza M, Theodorou GL, et al. Clinical relevance of balance between type 1 and type 2 immune responses of lymphocyte subpopulations in aplastic anaemia patients. Br J Haematol 2004; 124:97-105.
28. Zeng W, Maciejewski JP, Chen G, et al. Limited heterogeneity of T cell receptor BV usage in aplastic anemia. J Clin Invest 2001; 108:765-73.
29. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD41 T cells expressing the FoxP3 transcription factor. Immunity 2009; 30:899-911.
30. Shi J, Ge M, Lu S, et al. Intrinsic impairment of CD4(1)CD25(1) regulatory T cells in acquired aplastic anemia. Blood 2012; 120:1624-32.
31. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004; 21:467-76.
32. Gu Y, Hu X, Liu C, et al. Interleukin (IL)-17 promotes macrophages to produce IL-8, IL-6 and tumour necrosis factor-alpha in aplastic anaemia. Br J Haematol 2008; 142:109-14.
33. de Latour RP, Visconte V, Takaku T, et al. Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood 2010; 116:4175-84.
34. Kordasti SY, Afzali B, Lim Z, et al. IL-17-producing CD4(1) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009; 145: 64-72.
35. Hirano N, Butler MO, Von Bergwelt-Baildon MS, et al. Autoantibodies frequently detected in patients with aplastic anemia. Blood 2003; 102:4567-75.
36. Feng X, Chuhjo T, Sugimori C, et al. Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood 2004; 104: 2425-31. [CrossRef]
37. Takamatsu H, Espinoza JL, Lu X, et al. Anti-moesin antibodies in the serum of patients with aplastic anemia stimulate peripheral blood mononuclear cells to secrete TNF-alpha and IFNgamma. J Immunol 2009; 182:703-10.
38. Qi Z, Takamatsu H, Espinoza JL, et al. Autoantibodies specific to hnRNP K: a new diagnostic marker for immune pathophysiology in aplastic anemia. Ann Hematol 2010; 89:1255-63.
39. Goto M, Kuribayashi K, Takahashi Y, et al. Identification of autoantibodies expressed in acquired aplastic anaemia. Br J Haematol 2013; 160:359-62.
40. Liu C, Li Z, Sheng W, et al. Abnormalities of quantities and functions of natural killer cells in severe aplastic anemia. Immunol Invest 2014; 43:491-503.
41. Solomou EE, Gibellini F, Stewart B, et al. Perforin gene mutations in patients with acquired aplastic anemia. Blood 2007; 109:5234-7.
42. Hanaoka N, Nakakuma H, Horikawa K, et al. NKG2D-mediated immunity underlying paroxysmal nocturnal haemoglobinuria and related bone marrow failure syndromes. Br J Haematol 2009; 146:538-45.
43. Hanaoka N, Kawaguchi T, Horikawa K, et al. Immunoselection by natural killer cells of PIGA mutant cells missing stressinducible ULBP. Blood 2006; 107:1184-91.
44. Wu Q, Zhang J, Shi J, et al. Increased bone marrow (BM) plasma level of soluble CD30 and correlations with BM plasma level of interferon (IFN)-gamma, CD4/CD8 T-cell ratio and disease severity in aplastic anemia. PLOS ONE 2014; 9:e110787.
45. Li J, Zhao Q, Xing W, et al. Interleukin-27 enhances the production of tumour necrosis factor-alpha and interferon-gamma by bone marrow T lymphocytes in aplastic anaemia. Br J Haematol 2011; 153:764-72.
46. Sloand E, Kim S, Maciejewski JP, et al. Intracellular interferongamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood 2002; 100:1185-91.
47. Young NS. Pathophysiologic mechanisms in acquired aplastic anemia. Hematol Am Soc Hematol Educ Program 2006:72-7. [CrossRef]
48. Liu CY, Fu R, Wang HQ, et al. Fas/FasL in the immune pathogenesis of severe aplastic anemia. Genet Mol Res 2014; 13:4083-4088.
49. Kakagianni T, Giannakoulas NC, Thanopoulou E, et al. A probable role for trail-induced apoptosis in the pathogenesis of marrow failure. Implications from an in vitro model and from marrow of aplastic anemia patients. Leuk Res 2006; 30:713-21.
50. Lin FC, Karwan M, Saleh B, et al. IFN-gamma causes aplastic anemia by altering hematopoietic stem/progenitor cell composition and disrupting lineage differentiation. Blood 2014; 124:3699-708.
51. Dufour C, Corcione A, Svahn J, et al. Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia. Br J Haematol 2001; 115:1023-31.
52. Peng J, Liu C, Zhu K, et al. The TNF2 allele is a risk factor to severe aplastic anemia independent of HLA-DR. Hum Immunol 2003; 64:896-901.
53. Gidvani V, Ramkissoon S, Sloand EM, et al. Cytokine gene polymorphisms in acquired bone marrow failure. Am J Hematol 2007; 82:721-4.
54. Lee YG, Kim I, Kim JH, et al. Impact of cytokine gene polymorphisms on risk and treatment outcomes of aplastic anemia. Ann Hematol 2011; 90:515-21.
55. Serio B, Selleri C, Maciejewski JP. Impact of immunogenetic polymorphisms in bone marrow failure syndromes. Mini Rev Med Chem 2011; 11:544-52.
56. Szabo SJ, Sullivan BM, Stemmann C, et al. Distinct effects of Tbet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science 2002; 295:338-42.
57. Solomou EE, Keyvanfar K, Young NS. T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood 2006; 107:3983-91.
58. Rizzo S, Killick SB, Patel S, et al. Reduced TGF-beta1 in patients with aplastic anaemia in vivo and in vitro. Br J Haematol 1999; 107:797-803.
59. Brummendorf TH, Maciejewski JP, Mak J, et al. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood 2001; 97:895-900. [CrossRef]
60. Kulasekararaj AG, Jiang J, Smith AE, et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood 2014; 124:2698-704.
61. Calado RT, Young NS. Telomere maintenance and human bone marrow failure. Blood 2008; 111:4446-55.
62. Han B, Liu B, Cui W, et al. Telomerase gene mutation screening in Chinese patients with aplastic anemia. Leuk Res 2010; 34: 258-60.
63. Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005; 352:1413-24.
64. Scheinberg P, Cooper JN, Sloand EM, et al. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA 2010; 304:1358-64.
65. Rufer N, Brummendorf TH, Chapuis B, et al. Accelerated telomere shortening in hematological lineages is limited to the first year following stem cell transplantation. Blood 2001; 97:575-7.
66. Gadalla SM, Savage SA. Telomere biology in hematopoiesis and stem cell transplantation. Blood Rev 2011; 25:261-9.
67. Young NS. Telomere biology and telomere diseases: implications for practice and research. Hematol Am Soc Hematol Educ Program 2010; 2010:30-5.
68. Dumitriu B, Feng X, Townsley DM, et al. Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia. Blood 2015; 125:706-9.
69. Zeng W, Chen G, Kajigaya S, et al. Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers. Blood 2004; 103:325-32.
70. Calado RT, Cooper JN, Padilla-Nash HM, et al. Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia. Leukemia 2012; 26:700-7. [CrossRef]
71. Uccelli,A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8:726-36.
72. Chao YH, Peng CT, Harn HJ, et al. Poor potential of proliferation and differentiation in bone marrow mesenchymal stem cells derived from children with severe aplastic anemia. Ann Hematol 2010; 89:715-23.
73. Li J, Yang S, Lu S, et al. Differential gene expression profile associated with the abnormality of bone marrow mesenchymal stem cells in aplastic anemia. PLOS ONE 2012; 7:e47764.
74. Li JP, Zheng CL, Han ZC. Abnormal immunity and stem/progenitor cells in acquired aplastic anemia. Crit Rev Oncol Hematol 2010; 75:79-93.
75. Li J, Lu S, Yang S, et al. Impaired immunomodulatory ability of bone marrow mesenchymal stem cells on CD4(1) T cells in aplastic anemia. Results Immunol 2012; 2:142-7.
76. Bacigalupo A, Valle M, Podesta M, et al. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol 2005; 33:819-27.
77. Bueno C, Roldan M, Anguita E, et al. Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease. Haematologica 2014; 99:1168-75.
78. Xu Y, Takahashi Y, Yoshimi A, et al. Immunosuppressive activity of mesenchymal stem cells is not decreased in children with aplastic anemia. Int J Hematol 2009; 89:126-7.
79. Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 2012; 22:167-79.
80. Fujimaki S, Harigae H, Sugawara T, et al. Decreased expression of transcription factor GATA-2 in haematopoietic stem cells in patients with aplastic anaemia. Br J Haematol 2001; 113:52-7.
81. Chao YH, Wu KH, Chiou SH, et al. Downregulated CXCL12 expression in mesenchymal stem cells associated with severe aplastic anemia in children. Ann Hematol 2015; 94:13-22.
82. Xu Y, Takahashi Y, Wang Y, et al. Downregulation of GATA-2 and overexpression of adipogenic gene-PPARgamma in mesenchymal stem cells from patients with aplastic anemia. Exp Hematol 2009; 37:1393-9.
83. Kamata M, Okitsu Y, Fujiwara T, et al. GATA2 regulates differentiation of bone marrow-derived mesenchymal stem cells. Haematologica 2014; 99:1686-96.
84. Chao YH, Tsai C, Peng CT, et al. Cotransplantation of umbilical cord MSCs to enhance engraftment of hematopoietic stem cells in patients with severe aplastic anemia. Bone Marrow Transplant 2011; 46:1391-2.
85. Xu L, Liu Z, Wu Y, et al. Cotransplantation of human umbilical cord mesenchymal and haplo-hematopoietic stem cells in patients with severe aplastic anemia. Cytotechnology 2014, in press.
86. Li XH, Gao CJ, Da WM, et al. Reduced intensity conditioning, combined transplantation of haploidentical hematopoietic stem cells and mesenchymal stem cells in patients with severe aplastic anemia. PLOS ONE 2014; 9:e89666.
87. Meyers G, Maziarz RT. Is it time for a change? The case for early application of unrelated allo-SCT for severe aplastic anemia. Bone Marrow Transplant 2010; 45:1479-88.
88. Viollier R, Socie G, Tichelli A, et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant 2008; 41:45-50.
89. Kosaka Y, Yagasaki H, Sano K, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as secondline treatment for children with severe and very severe aplastic anemia. Blood 2008; 111:1054-9. [CrossRef]
90. Kim H, Lee KH, Yoon SS, et al. Allogeneic hematopoietic stem cell transplant for adults over 40 years old with acquired aplastic anemia. Biol Blood Marrow Transplant 2012; 18: 1500-8.